Hims & Hers Health, Inc. (HIMS)
Hims & Hers is a digital health platform that connects people with licensed medical professionals for treatments related to hair loss, skin care, and mental health.
Is Hims & Hers Health, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Very high gross margins suggest a strong underlying business model. Worth weighing: The company is not yet consistently profitable. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Hims & Hers Health, Inc. actually fallen?
Over the last 2 years of daily prices, Hims & Hers Health, Inc. fell as much as −79% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Becoming a dominant household name in digital health
Regulatory changes impacting online prescription models
What does Hims & Hers Health, Inc. do?
The company operates an online shop and consultation service that makes it easier to get prescriptions for common personal health concerns delivered straight to your door. The cash rolls in from selling these subscription-based treatments and charging for the virtual doctor visits that facilitate them. Turning their high sales volume into consistent profit is the challenge, as they are currently hovering right around the break-even point.
On our factor screen it looks strongest on quality and value, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 4% over the year
- !Carries a lot of debt - roughly 2.5x its equity
- Very high gross margins suggest a strong underlying business model
- Convenient digital-first approach appeals to modern consumers
- Subscription model provides a predictable stream of recurring revenue
- Value screens low (28/100)
- Quality screens low (29/100)
- Growth screens low (24/100)
- Momentum screens low (19/100)
- Income screens low (16/100)
What do Hims & Hers Health, Inc.'s numbers mean?
How much money does Hims & Hers Health, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Hims & Hers Health, Inc. pay a dividend?
No - Hims & Hers Health, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Hims & Hers Health, Inc. report earnings, and how did recent quarters go?
Hims & Hers Health, Inc. is next scheduled to report on about 2026-08-10 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-11 | $0.13 | $-0.19 | Missed -244% |
| 2026-02-23 | $0.19 | $0.22 | Beat +21% |
| 2025-11-03 | $0.23 | $0.28 | Beat +20% |
| 2025-08-04 | $0.23 | $0.29 | Beat +26% |
| 2025-05-05 | $0.23 | $0.28 | Beat +24% |
| 2025-02-24 | $0.22 | $0.23 | Beat +4% |
Across the last 6 quarters here, Hims & Hers Health, Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Hims & Hers Health, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Hims & Hers Health, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Very high gross margins suggest a strong underlying business model
- Convenient digital-first approach appeals to modern consumers
- Subscription model provides a predictable stream of recurring revenue
- The company is not yet consistently profitable
- High beta indicates the share price can be quite a rollercoaster
- Revenue growth: How fast the company's sales grew versus a year ago. has slowed down recently
- Changes in healthcare regulations could disrupt the online prescription process
- Intense competition from both established pharmacies and new digital entrants
- High reliance on marketing spend to acquire new customers
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained shift to consistent net profitability
- A significant change in government rules regarding telehealth prescriptions
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.